Trial intelligence / Profile preview

Phase III study of Hemay022 plus aromatase inhibitor in postmenopausal HER2-positive/ER-positive advanced breast cancer after trastuzumab-containing therapy

CTR20212304Phase 3Active

Sponsor

Xiajiang Hemei Pharmaceutical

Start

Jan 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1